Bert Vogelstein, Johns Hopkins oncology researcher
ManaT Bio, a KRAS biotech from Bert Vogelstein and Catalio, targets $153M with Third Rock partner as CEO
A new immunotherapy biotech from famed Johns Hopkins oncology researchers Bert Vogelstein and Drew Pardoll is in the works, with a sizable $153 million financing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
